SRNEQ Stock Price, News & Analysis

SRNEQ OTC

Company Description

SRNEQ (OTC: SRNEQ) is a publicly traded research and development in biotechnology company in the Professional, Scientific, and Technical Services sector.

SRNEQ stock has declined 100.0% over the past year.

This page provides a comprehensive overview of SRNEQ stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart

$—

0.00%

0.00

Last updated:

-100%

Performance 1 year

$0.0

Market Cap

0.0

Shares outstanding

SRNEQ (SRNEQ) stock. Over the past 12 months, the stock has lost 100.0%.

Latest News

View All

September 22, 2023

-2.54%

Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company

September 12, 2023

+3.57%

Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19

clinical trial covid-19

September 7, 2023

+36.74%

Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients

clinical trial

August 8, 2023

-10.35%

Sorrento Therapeutics, Inc. Announces Auction for Sale of Scilex Securities and Bankruptcy Court Approval of Stalking Horse Bid

July 27, 2023

+6.67%

Sorrento Issues a “FAQ” in Response to Large Number Of Urgent Requests from Scilex Dividend Short Holders and/or Record Holders

dividends

July 5, 2023

+4.82%

Sorrento Announces Positive Phase IIa Study Results of Abivertinib for the Treatment of Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) and Its Plan for a Pivotal Phase III Study

clinical trial

SRNEQ has 10 recent news articles. Of the recent coverage, 7 articles coincided with positive price movement and 3 with negative movement. Key topics include clinical trial, covid-19, dividends. View all SRNEQ news →

SEC Filings

View All

No SEC filings available for SRNEQ.

Financial Highlights

View Full Financials

—

Revenue (TTM)

—

Net Income (TTM)

—

Diluted EPS (TTM)

—

Operating Cash Flow

—

Net Profit Margin

—

Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months

SRNEQ Company Profile & Sector Positioning

SRNEQ (SRNEQ) operates in the Research and Development in Biotechnology industry within the broader Professional, Scientific, and Technical Services sector and is listed on the OTC.